Holen Sie sich die Stockscreener-App
0.7286
7.15%
0.0486
Handel nachbörslich:
.72
-0.0086
-1.18%
Schlusskurs vom Vortag:
$0.68
Offen:
$0.7
24-Stunden-Volumen:
59,572
Relative Volume:
0.05
Marktkapitalisierung:
$3.08M
Einnahmen:
$112.00K
Nettoeinkommen (Verlust:
$-15.75M
KGV:
-0.0488
EPS:
-14.9263
Netto-Cashflow:
$-13.33M
1W Leistung:
+4.93%
1M Leistung:
-41.71%
6M Leistung:
-71.95%
1J Leistung:
+507.77%
1-Tages-Spanne:
$0.6702
$0.7286
1-Wochen-Bereich:
$0.6601
$0.7645
52-Wochen-Spanne:
$0.0632
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.7286 | 2.87M | 112.00K | -15.75M | -13.33M | -14.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech Inc. Signs Dealer-Manager Agreement with Maxim Group LLC for Rights Offering – SEC Form 8-K Filing March 2026 - Minichart
Cancer-drug developer AIM ImmunoTech draws $1.8M in $1,000 rights sale - Stock Titan
AIM ImmunoTech Announces Closing of its Rights Offering - Caledonian Record
AIM ImmunoTech Completes Series G Preferred Rights Offering - TipRanks
AIM ImmunoTech completes rights offering, creates new preferred stock series - Investing.com
AIM ImmunoTech Appoints Equiniti as Warrant Agent for $1.8 Million Rights Offering - TradingView
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Bitget
AIM ImmunoTech (AIM) Projects $1.8M from Rights Offering - GuruFocus
Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million - TradingView
AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire
AIM Collaborates with Thermo Fisher for Phase 3 Trial of Amplige - GuruFocus
AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer. - Bitget
Experimental pancreatic cancer drug Ampligen moves toward Phase 3 test - Stock Titan
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) Updates Rights Offering Terms - GuruFocus
AIM ImmunoTech Reminds Stockholders of March 3, 2026 - GlobeNewswire
AIM ImmunoTech (NYSE American: AIM) offers 12,000 Units and 24M warrants - Stock Titan
Investors get $1,000 AIM unit with 2,000 warrants — but clock is ticking - Stock Titan
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - Bitget
AIM Should I Buy - Intellectia AI
AIM ImmunoTech (AIM) Extends Rights Offering Subscription Period - GuruFocus
AIM ImmunoTech Inc. recently announced that it will extend the exercise period for shareholder subscription rights in its previously announced stock offering plan. - Bitget
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 - The Manila Times
Aim Immunotech Announces Extension Of Subscription Period - TradingView
AIM cancer-drug investors get new March 3 deadline, use-it-or-lose-it rights - Stock Titan
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi - Indian Pharma Post
AIM ImmunoTech (AIM) Reports Progress in Pancreatic Cancer Study - GuruFocus
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Bitget
AIM ImmunoTech Announces Planned Milestones in the Ongoing - GlobeNewswire
New pancreatic cancer trial pairs AIM drug with AstraZeneca's Imfinzi - Stock Titan
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer - ChartMill
AIM ImmunoTech at Virtual Investor Closing Bell: Strategic Focus on Pancreatic Cancer By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
AIM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Merger Talk: Will AIM ImmunoTech Inc. stock outperform global peersEarnings Beat & Verified Chart Pattern Trade Signals - mfd.ru
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - Bitget
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - The Manila Times
AIM ImmunoTech at Corporate Connect: Ampligen’s Role in Pancreatic Cancer - Investing.com Canada
AIM: Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer - TradingView
AIM ImmunoTech launches rights offering to raise $12 million - Intellectia AI
AIM ImmunoTech Launches Rights Offering for Common Stock Holders - GuruFocus
Aim Immunotech Announces Commencement Of Rights Offering - TradingView
AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewswire
Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan
ImmunoTech (AIM) updates S-1 with exhibits-only Amendment No. 3 - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
AIM ImmunoTech to Participate in Corporate Connect Webinar - Intellectia AI
AIM ImmunoTech to Participate in the Corporate Connect - GlobeNewswire
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - 富途牛牛
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):